Grand Pharma’s Y-90 SIRT product enters China commercial insurance drug list

Commercial insurance listing is often the practical bridge between NRDL exclusion and real patient access in China, so Yigantai's inclusion matters less as a reimbursement milestone than as a distribution unlock for a therapy that requires specialised nuclear-medicine infrastructure. The significance concentrates on Grand Pharma's oncology franchise and on hospitals weighing whether to build out SIRT capability. The open question is whether commercial coverage translates into actual procedural volume, given that Y-90 logistics and centre readiness — not list status — typically gate adoption.